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Abstract Taurine (2-aminoethanesulfonic acid) is a free
amino acid found ubiquitously in millimolar concentrations
in all mammalian tissues. Taurine exerts a variety of bio-
logical actions, including antioxidation, modulation of ion
movement, osmoregulation, modulation of neurotransmit-
ters, and conjugation of bile acids, which may maintain
physiological homeostasis. Recently, data is accumulating
that show the effectiveness of taurine against diabetes
mellitus, insulin resistance and its complications, including
retinopathy, nephropathy, neuropathy, atherosclerosis and
cardiomyopathy, independent of hypoglycemic effect in
several animal models. The useful effects appear due to the
multiple actions of taurine on cellular functions. This
review summarizes the beneﬁcial effects of taurine sup-
plementation on diabetes mellitus and the molecular
mechanisms underlying its effectiveness.
Keywords Taurine  Diabetic mellitus  Diabetic
complications  Obesity  Insulin resistance
Introduction
Taurine (2-aminoethanesulfonic acid) is widely distributed
and is found in millimolar concentration in mammalian
tissues. Many evidences support that taurine is a
cytoprotective agent in a variety of tissues. Taurine mod-
ulates a variety of cellular functions, including antioxida-
tion, modulation of ion movement, osmoregulation,
modulation of neurotransmitters and conjugation of bile
acids etc. (Huxtable 1992; Satoh 1998; Schaffer et al. 2000;
Sjovall 1959). The source of taurine in body is biosynthesis
and dietary intake. Taurine is synthesized from methionine
and cysteine mainly in the liver. It is well-known that
biosynthetic capacity of taurine is very low in human and is
absent in cats, while rodents have high synthetic capacity
(Hansen 2001). On the other hand, dietary taurine is
ingested from meat and sea food. Especially, sea food is
rich in taurine. Yamori et al. (2001) demonstrated that
urinary taurine excretion as a marker of taurine intake
inversely correlated with mortality rate caused by ischemic
heart diseases in world wide epidemiological study.
Moreover, taurine depletion by taurine-deﬁcient diet in cats
causes various pathological conditions, including retinal
degeneration, reproductive failure and dilated cardiomy-
opathy (Hayes et al. 1975; Pion et al. 1987; Sturman 1991).
Therefore, taurine seems an essential nutrient and its
deﬁciency may cause various tissue disorders in human.
Moreover, treatment of taurine beneﬁts many kinds of
pathologies. The accumulating data show the effectiveness
of taurine supplementation against both insulin dependent,
non-insulin dependent diabetes mellitus and insulin resis-
tance (Franconi et al. 2004, 2006; Hansen 2001; Schaffer
et al. 2009). In addition, taurine supplementation is bene-
ﬁcial to diabetic complications, including retinopathy,
nephropathy, neuropathy, atherosclerosis and cardiomy-
opathy. These useful effects appear due to the multiple
actions of taurine on cellular functions. This review sum-
marizes the beneﬁcial effects of taurine supplementation on
diabetes and the molecular mechanisms underlying the
effectiveness.
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The effect of taurine on type 1 diabetic models
The effect of taurine administration for type 1 diabetes has
been well investigated. Treatment of taurine before dia-
betic onset suppressed hyperglycemia and lowered plasma
glycated hemoglobin, cholesterol and triglyceride in STZ-
induced type 1 diabetic rats (Alvarado-Vasquez et al. 2003;
Tokunaga et al. 1979, 1983). Moreover, taurine reduced
plasma lipid peroxidation products induced in type 1 dia-
betes mellitus. The prevention of hyperglycemia by taurine
was also reported in alloxan-induced type 1 diabetic rabbits
(Tenner et al. 2003; Winiarska et al. 2009). Importantly, it
has been reported that treatment of taurine started from the
time-point of diabetic onset failed to improve hypergly-
cemia in type 1 diabetic animals (Goodman and Shihabi
1990), indicating that lowering effect of taurine on blood
glucose level in type 1 models may be due to the protection
of beta cells from STZ or alloxan (Chang and Kwon 2000;
Gavrovskaya et al. 2008). Interestingly, taurine supple-
mentation from 2 days later of STZ injection prolonged
survival in diabetic rats (Di Leo et al. 2004). This obser-
vation indicates that taurine may confer the resistance
against some stresses induced by hyperglycemia, which
may associate with the beneﬁcial role against the compli-
cations, as described below.
Non-obese diabetic (NOD) mice genetically develop
autoimmune diabetes caused by inﬁltration of the pancre-
atic islets by mononuclear leucocytes. Taurine supple-
mentation starting before birth (pregnant mice were
received a diet supplemented with taurine) until weaning
signiﬁcantly increased in pancreatic islet mass in NOD
mice (Arany et al. 2004), suggesting that taurine alters islet
development. Moreover, taurine treatment delayed the
onset time of diabetes, and 20% of treated female mice
remained free of diabetes.
The effect of taurine on obese-induced diabetic models
The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is a
model of non-insulin dependent diabetes, which exhibits
hyperglycemia and insulin resistance and has accumulated
abdominal fat as compared to the normal rats. It has been
demonstrated that taurine supplementation improved
hyperglycemia and insulin resistance in OLETF rats
(Harada et al. 2004; Nakaya et al. 2000). Taurine also
suppressed the increase in serum triglyceride and cholesterol,
but not body weight and abdominal fat mass. Whereas it
was expected that taurine could enhance the calorie con-
sumption and/or lipid oxidation, taurine supplementation
did not increase but decrease the energy expenditure and
did not alter the lipid oxidation in OLETF rats (Harada
et al. 2004). Therefore, the other pathways may underlie.
Concerning with body weight and fat mass, taurine sup-
plementation prevented the high fat diet-induced increase
in body weight as well as fat mass in high fat diet-induced
obese mice (Tsuboyama-Kasaoka et al. 2006). Then, the
effect of taurine on obesity may differ dependent on animal
species and/or experimental procedures.
The effect of taurine on fructose-fed rat model
High fructose diet impairs glucose tolerance and insulin
sensitivity, taurine supplementation suppressed hypergly-
cemia and insulin resistance in high fructose-fed rat model
(Nandhini et al. 2004, 2005; El Mesallamy et al. 2010).
Furthermore, taurine supplementation to high fructose-fed
rats decreased in the biomarkers of oxidative stress, such as
lipid peroxidation and conjugated dines. Additionally,
while taurine improved urinary kallikrein activity in fruc-
tose-fed rats, the effect of taurine supplementation was
prevented by co-administration of Hoe 140, a kinin B2
receptor antagonist (Nandhini and Anuradha 2002, 2004).
Since kinins inﬂuence insulin release and insulin action,
this action may be involved in the molecular mechanism of
the effect of taurine against insulin resistance.
The effect of taurine on insulin secretion and insulin
sensitivity in acute glucose or lipid infusion models
Prolonged elevation of glucose is associated with insulin
resistance. While 6-h infusion of high glucose induced a
decrease in insulin-stimulated peripheral glucose uptake,
co-infusion of taurine prevented the defect of glucose
uptake (Haber et al. 2003). Furthermore, co-infusion of
taurine suppressed lipid peroxidation induced by high
glucose infusion in soleus muscle, indicating that anti-
oxidative role of taurine in skeletal muscle is involved in
the pathway of effectiveness against peripheral insulin
resistance. However, taurine failed to prevent a decrease in
glucose-stimulated insulin secretion and an increase in
reactive oxygen induced by 48-h infusion of high glucose
(Tang et al. 2007). On the other hand, some reports dem-
onstrated various protective actions of taurine, such as the
modulation of mitochondrial calcium handling and the
stabilization of protein folding, against high glucose
exposure in the cultured beta cells (Han et al. 2004; Kaniuk
et al. 2007).
Meanwhile, the beneﬁcial effect of taurine on islet
dysfunction induced by free fatty acid was observed
(Oprescu et al. 2007). While 48-h intravenous infusion of
oleate decreased the glucose-stimulated insulin secretion,
co-infusion of taurine prevented defective insulin secretion
in islets induced by oleate. Furthermore, taurine suppressed
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123oleate-induced ROS production in islets. Moreover, taurine
also prevented hepatic insulin resistance induced by intra-
venous infusion of fatty acids (Wu et al. 2010). This
beneﬁcial effect was accompanied by inhibition of fatty
acid-induced oxidative stress and JNK1 activation which
impairs insulin signaling. These reports indicate the bene-
ﬁcial effect of taurine against lipotoxicity in islets and
livers, which in turn may contribute to the prevention of
diabetic onset in obesity.
The effect of taurine against diabetic complications
and its molecular mechanisms
Alteration of taurine level in diabetes
Plasma and tissue taurine level are known to alter in a
variety of pathophysiological conditions. Plasma taurine
concentration in patients with insulin-dependent diabetes
mellitus (IDDM) was signiﬁcantly lower than in control
subjects (Franconi et al. 1995, 1996). Consistently, the
reduction of plasma taurine level has been demonstrated in
STZ- or alloxan-induced diabetic animals (Franconi et al.
1996; Trachtman et al. 1995). In case of type2 diabetes,
plasma taurine level is lower in the patients than non-dia-
betic healthy subjects (De Luca et al. 2001; Merheb et al.
2007). Since taurine deﬁciency associates with dysfunction
in various tissues (Hayes et al. 1975; Pion et al. 1987;
Sturman 1991), a decrease in taurine level in diabetic
subjects may be involved in the diabetic complications.
The role of taurine against the production of advanced
glycation end-products and modiﬁed LDL
Hyperglycemia accelerates non-enzymatic glycation of
protein and causes the accumulation of advanced glycation
end products (AGEs). It is known that AGEs play a key
role in the development of diabetic complications, such as
nephropathy and microvascular diseases. Since taurine has
a high reactivity with aldehyde as compared to the other
amino acids (Ogasawara et al. 1993), the preventive actions
of taurine on the productions of AGEs in diabetes are
expected. Indeed, taurine inhibited the AGE formation in
vitro (Nandhini et al. 2004; Nandhini and Anuradha 2003;
Selvaraj et al. 2006). Consistently, taurine supplementation
prevented an increase in the plasma glycated proteins, such
as fructosamine and glycated hemoglobin, in high fructose-
fed rats (Nandhini et al. 2004).
While the modiﬁed LDL also contributes to develop-
ment of vascular complications, some actions of taurine is
likely to associate with prevention of LDL modiﬁcation.
The reactivity of taurine with aldehyde is also likely to
contribute to decrease in malondialdehyde-related LDL
modiﬁcation (Ogasawara et al. 1993). Moreover, taurine
also has the scavenging action for hypochlorous acid
(HClO), while HClO, produced by myeloperoxidase in
neutrophils and macrophages, possesses the antimicrobial
properties and is also involved in oxidation of LDL
(Pennathur and Heinecke 2007). In type 2 diabetic models,
high myeloperoxidase activity has been found in the ves-
sels of diabetic obese rats (Zhang et al. 2004), indicating
that HClO may contribute to increase in oxidized LDL in
diabetes. Moreover, lowering effect of taurine on the pro-
duction of LDL-cholesterol itself may contribute the
reduction of oxidized LDL (Bellentani et al. 1987; Gandhi
et al. 1992; Nakamura-Yamanaka et al. 1987; Yokogoshi
et al. 1999). The increased serum level of LDL cholesterol
in STZ-treated diabetic mice was normalized by the
chronic administration of taurine (Mochizuki et al. 1999;
Nanami et al. 1996).
Endothelial dysfunction
Most of diabetic complications are associated with vascular
disorder. Microangiopathy causes retinopathy, nephropathy
and neuropathy, whereas macroangiopathy causes cardio-
myopathy and atherosclerosis. In STZ-treated diabetic
mice, it has been demonstrated that the chronic taurine
supplementation normalized the acetylcholine-induced
relaxation of aortic rings, while the vasodilatation capacity
is attenuated (Kamata et al. 1996; Wang et al. 2008).
Furthermore, pre-incubation of the tissues with taurine for
2-h ex vivo improved both the enhanced response to nor-
epinephrine and the attenuated response to acetylcholine in
aorta ring from STZ-treated diabetic rats (Abebe 2008).
These data illustrate the protective action of taurine on the
impaired endothelium-dependent vasodilator response in
hyperglycemia.
A variety of molecular mechanisms underlie the bene-
ﬁcial role of taurine against endothelial dysfunction in
diabetes mellitus (summarized in Fig. 1). As described
above, lowering effect of taurine on AGE and modiﬁed
LDL may be involved in the molecular pathway of bene-
ﬁcial effect of taurine. Additionally, HClO consumes the
nitric oxide and in turn causes vasoconstriction and endo-
thelial dysfunction (Pennathur and Heinecke 2007). Taurine
may increase the bioavailability of NO through scavenging
HClO. Furthermore, taurine suppressed the expressions of
vascular cell adhesion molecule-1 (VCAM-1) and inter-
cellular adhesion molecule-1 (ICAM-1) induced by high
glucose in cultured endothelial cells (Ulrich-Merzenich
et al. 2007). Consistently, taurine supplementation started
after the diabetes onset in STZ-treated diabetic rats pre-
vented the induction of ICAM-1 and lectin-like oxidized
LDL receptor-1 (LOX-1), which is responsible for the
incorporation of oxidized LDL into cells, in aortas (Wang
The potential usefulness of taurine on diabetes mellitus and its complications 1531
123et al. 2008). Furthermore, while acute hyperglycemiainduced
by intravenous infusion of glucose activated leucocyte
adhesion and migration to endothelium and increased in
endothelial ICAM-1 and apoptosis in rats, taurine supple-
mentation for 5 days prior to the experiment prevented
leucocyte actions and the elevation of ICAM-1 and apop-
totic cell death (Casey et al. 2007). Therefore, taurine may
prevent the leukocyte-endothelial cell interaction and
endothelial apoptosis enhanced by hyperglycemia.
Diabetic nephropathy
It has been reported that taurine supplementation started
concurrently with STZ injection reduced albuminuria and
diminished glomerulosclerosis and tubulointerstitial ﬁbro-
sis (Trachtman et al. 1995). More recently, it has been
demonstrated that the taurine administration from fourth
month later of the induction of diabetes signiﬁcantly sup-
pressed further increase in urinary protein excretion in
diabetic rats, accompanied by the reduction of mesangial
extracellular matrix expansion, TGF-b expression and
oxidative stress in the renal glomerulus in rats (Higo et al.
2008). In vitro study also demonstrated that taurine treat-
ment suppressed the increases in lipid peroxidation and
TGF-b by high glucose in renal proximal tubule cells (Park
et al. 2001). Moreover, taurine attenuated impairment of
cellular growth and tubule cell hypertrophy induced by
high glucose, associated with the suppression of high glu-
cose-induced signal activations including MAPK cascade
and STAT3 (Huang et al. 2007). Furthermore, taurine
attenuated the induction of cytochrome P450 2E1 which
metabolizes a variety of endogenous and exogenous com-
pounds and is a potential source of ROS in kidney of
STZ-treated diabetic rats (Yao et al. 2009). Taurine also
attenuated cell hypertrophy and ﬁbrosis induced by AGE
exposure in renal tubular epithelial cells (Huang et al.
2008). Moreover, it has been reported that taurine
suppressed the induction of ﬁbrosis-related genes in AGE-
treated renal tubular cells (Huang et al. 2009). Therefore,
taurine may prevent renal injury and ﬁbrosis in diabetic
animals through suppression of ROS induced by glucose
and AGE in kidney.
Diabetic retinopathy
In STZ-induced diabetic model, taurine supplementation
after diabetic onset effectively improved the changes in
ultrastructureandattenuatedinductionofglialﬁbrillaryacid
protein (GFAP), a marker of gliosis, and apoptosis in retinal
glial cells of STZ-treated diabetic rats without the effect on
plasma glucose concentration (Yu et al. 2008; Zeng et al.
2009, 2010a), indicating the beneﬁcial role of taurine on
diabetic retinopathy. Furthermore, the taurine supplemen-
tation in STZ-treated rats signiﬁcantly decreased in retinal
carbonyl dienes (Di Leo et al. 2002, 2003). Additionally,
taurine supplementation attenuated the induction of retinal
VEGF, which associates with vascularization, in STZ-dia-
betic rats, suggesting that taurine may normalize the retinal
vascular function in diabetes (Obrosova et al. 2001b; Zeng
et al. 2009). Furthermore, while elevation of glutamate in
retina is associated with the development of diabetic reti-
nopathy,taurinepreventedtheelevationofretinalglutamate
content and reduction of the proteins involved in glutamate
uptake and degradation in STZ-treated diabetic rats (Zeng
et al. 2009). Consistently, taurine suppressed high glucose-
induced defect of glutamate uptake and degradation in cul-
tured Muller cells (Zeng et al. 2010b).
Diabetic cataract
Taurine is known to be the most abundant free amino acid
in eye lens, and lens taurine level is decreased in diabetic
cataract group in STZ-treated diabetic rats (Anthrayose and
Shashidhar 2004; Malone et al. 1990; Vilchis and Salceda
Fig. 1 Schematic
representation of potential
pathways involved in the
beneﬁcial action of taurine
against hyperglycemia-induced
endothelial dysfunction. Taurine
can inhibit (i) AGE production,
(ii) oxidized LDL (oxLDL)
production through scavenging
malondialdehyde (MDA) and
hypochlorous acid (HClO), (iii)
HClO-dependent NO reduction,
and (iv) leulocyte–endothelium
interaction
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1231996). Chronic taurine supplementation reduced malondi-
aldehyde level in lens of STZ-induced diabetic rats
(Obrosova and Stevens 1999). Furthermore, although tau-
rine did not improve opacity of eye lens induced by the
exposure to high glucose medium for 6 days in cultured
lens, taurine inhibited protein carbonylation induced by
high glucose (Son et al. 2007). These studies indicate that
taurine protects the lens from oxidative stress induced by
hyperglycemia, while the effect of taurine against cataract
is arguable.
Diabetic neuropathy
It is well-known that sorbitol accumulation in the nerve is
associated with diabetic peripheral neuropathy. When
intracellular glucose is increased in hyperglycemic condi-
tion, excessive glucose is metabolized to sorbitol through
aldose reductase. Organic osmolytes, including sorbitol,
taurine and myo-inositol, are regulated in response to the
change of extracellular osmolality to maintain the cell
volume. Stevens demonstrated that taurine and myo-inositol
are decreased in nerve of STZ-treated diabetic rats, whereas
administration of aldose reductase inhibitor attenuated the
depletion of taurine and myo-inositol (Stevens et al. 1993),
suggesting that excessive accumulation of sorbitol led to the
depletion of other organic osmolytes. Interestingly, the
exposure of cells to high glucose reduces the expression of
taurine transporter, whereas the treatment of an aldose
reductase inhibitor or an antioxidant with the high glucose
reversed the expression of taurine transporter (Askwith
et al. 2009; Stevens et al. 1999), suggesting the crucial role
of sorbitol in the regulation of intracellular taurine con-
centration. While diabetic neuropathy is observed in STZ-
treated diabetic model, taurine supplementation improved
the defective nerve functions, such as nerve conductance
deﬁcits and hyperalgesia, and ameliorated the deﬁcit of
nerve blood ﬂow (Li et al. 2005b; Obrosova et al. 2001a, b;
Pop-Busui et al. 2001; Stevens et al. 1993). Taurine sup-
plementation reduced the oxidative stress in nerves and
prevented the impairment of calcium handling in sensory
neuron of STZ-treated diabetic rats (Li et al. 2005b).
Additionally, a decrease in nerve growth factor (NGF) in
STZ-treated rats was prevented by taurine supplementation
(Obrosova et al. 2001a). Similarly, usefulness of taurine
against diabetic peripheral neuropathy, including deﬁcits of
hind limb sciatic motor and digital sensory nerve conduc-
tion velocity, nerve blood ﬂow, and sensory thresholds, was
observed in Zucker diabetic fatty rats (Li et al. 2006).
Atherosclerosis and thrombosis
Diabetes is a major risk factor of atherosclerosis. While
there are several reports on the beneﬁcial effects of taurine
against atherosclerosis (Kondo et al. 2000; Murakami et al.
1999a, 1999b, 2002), no evidence has been demonstrated
in the diabetic models. Since endothelial dysfunction and
accumulation of oxidized LDL in vessel are the critical
features of atherosclerosis, various actions of taurine in
endothelial cells mentioned above, such as lowering oxi-
dized LDL and anti-apoptosis, can work effectively on
atherosclerosis in diabetes.
Moreover, platelet activation and aggregation caused
by atherosclerosis are the critical events in thrombosis. It
is known that platelet function alters in diabetic subjects,
which may sensitize the platelet for stresses to generate
thrombi. It has been reported that platelet taurine level as
well as plasma taurine level is decreased in both type 1
and type 2 diabetic patients (De Luca et al. 2001; Fran-
coni et al. 1995). Because taurine depletion causes an
increase in platelet sensitivity to aggregation (Hayes et al.
1989), it has been hypothesized that taurine supplemen-
tation can prevent platelet aggregation in diabetic patients.
Franconi et al. (1995) reported that taurine supplementa-
tion at 1.5 g/day for 90 days in IDDM patients suppressed
platelet aggregation induced by arachidonic acid in the
isolated platelet. Additionally, they demonstrated the pre-
incubation of taurine inhibits arachidonic acid-induced
aggregation in platelet from diabetic patients, but not in
platelet from control subjects. Spohr et al. (2005) dem-
onstrated that taurine supplementation at 1.5 g/day for
8 weeks had no effect on ADP-stimulated platelet
aggregation in high risk subjects with a positive family
history of NIDDM.
Diabetic cardiomyopathy
Unlike the other tissues, cardiac taurine level increases in
STZ-treated diabetic models and does not alter in obese-
induced diabetic models (Militante et al. 2000). Elevation
of cardiac taurine level seems the feature of cardiomyop-
athy, since its elevation has also been reported in the ani-
mal models or patients with congestive heart failure
(Huxtable and Bressler 1974). Although the biological
signiﬁcance of the elevation of taurine level in the failing
heart is still unveiled, the elevated taurine is expected to
modulate glycolytic capacity, such as pyruvate dehydro-
genase phosphorylation, in diabetic cardiomyopathy
(Militante et al. 2000). Recently, Li et al. (2005a) reported
that taurine supplementation started after the development
of cardiomyopathy prevented an increase in heart weight
and improved the impaired -dp/dt max but not ?dp/dt
max. Furthermore, taurine supplementation suppressed the
reduction of Bcl-2 expression in STZ-treated diabetic car-
diomyopathy rats, indicating that anti-apoptotic action of
taurine may be involved in the protective effect of taurine
against diabetic cardiomyopathy.
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The clinical usefulness of taurine on diabetes has been
evaluated in some clinical studies (listed in Table 1). In
clinical trial for type 1 diabetic patients, Elizarova and
Nedosugova (1996) investigated the effect of taurine on
hyperglycemia in type 1 diabetic patients (n = 10) who
had been already medicated with insulin. Additive sup-
plementation of taurine (0.5 g twice a day) improved the
carbohydrate metabolism and decreased in triglyceride. In
the other study, however, Franconi et al. (1995) reported
that the administration of taurine (1.5 g per day) for 90 day
did not modify glucose metabolism in IDDM patients
(n = 39). Clinical usefulness on type 1 diabetes is still
arguable.
There are some clinical trials of taurine supplementation
on the patients with type 2 diabetes mellitus. Chauncey
et al. (2003) tested the hypoglycemic effect of taurine on
type2 diabetes patients (n = 32), and they showed that
taurine supplementation (3 g per day) for 4 month
increased in plasma taurine level but did not change HbA1c
level and the plasma lipid peroxide level compared to
placebo group. Brons et al. (2004) also tested the effect of
taurine in overweight non-diabetic men (n = 20) in
crossover study. Although plasma taurine level was ele-
vated after taurine administration (1.5 g per day) for
8 weeks, taurine had no effects on insulin secretion or
sensitivity, and on plasma lipid level. These studies con-
cluded that taurine does not inﬂuence hyperglycemia and
insulin resistance in type 2 diabetic patients, inconsistent
with animal studies. However, it should be noted that these
clinical studies have some limitations such as other medi-
cations, given dose of taurine, duration of trial etc. On the
other hand, usefulness of taurine supplementation against
the impairment of insulin sensitivity was reported in the
crossover clinical study by Xiao et al. (2008). They dem-
onstrated the effect of taurine against chronic elevation of
plasma fatty acids induced by the intravenous infusion of
Intralipid (20% soybean oil, 1.2% egg phospholipids,
2.25% glycerin in water, heparin) on non-diabetic men who
were either overweight or obese (n = 6). While 48-h
infusion of intravenous lipid induced insulin resistance, a
2-week pretreatment of taurine (3 g per day) before lipid
infusion improved the impaired insulin sensitivity and
prevented the rise in lipid peroxidation products in plasma,
indicating that oral taurine supplementation ameliorates
fatty acid-induced insulin resistance in humans, possibly
due to reducing oxidative stress.
Concerning diabetic nephropathy, Nakamura et al.
(1999) tested the taurine supplementation (3 g per day) on
the patients with microalbuminemia of type 2 diabetes and
treatment was continued for 12 months in intergroup trial
(n = 10 each group). They demonstrated that taurine sup-
plementation had no beneﬁt against microalbuminemia and
the biomarkers for ﬁbrosis, such as serum collagen IV and
plasma Matrix metalloproteinase-9.
Meanwhile, Moloney et al. (2010) recently reported the
beneﬁcial effect of taurine on endothelial dysfunction in
type 1 diabetic patients in crossover study. While arterial
stiffness and ﬂow-mediated dilatation of brachial artery,
Table 1 Clinical studies with diabetes and complications
Article Subjects Duration Dose (/day) Endpoint Result
Diabetes
Franconi et al. (1995) IDDM patients (n = 39) 90 days 1.5 g Glucose metabolism NC
Elizarova and Nedosugova
(1996)
IDDM patients (n = 10) 30 days 1 g Glucose metabolism Improved
Triglyceride Decreased
Chauncey et al. (2003) NIDDM patients (n = 32) 4 months 3 g HbA1c NC
Plasma lipid peroxide level NC
Brons et al. (2004) Overweight non-diabetic
men (n = 20)
8 weeks 1.5 g Insulin secretion NC
Plasma lipid level NC
Xiao et al. (2008) Overweight non-diabetic
men (n = 6).
2 weeks 3 g Insulin sensitivity impaired by 48-h
infusion of intravenous lipid
Improved
Lipid peroxidation products Decreased
Complications
Nakamura et al. (1999) NIDDM patients with
microalbuminemia
(n = 10 each group)
12 months 3 g Microalbuminemia NC
Biomarkers for ﬁbrosis NC
Moloney et al. (2010) IDDM patients (n = 9) 2 weeks 1.5 g Hyperglycemia NC
Endothelium-dependent reaction Improved
NC Not changed
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123which are endothelium-dependent reactions, were low in
diabetic patients as compared to control subjects, taurine
supplementation (1.5 g per day) for 2 weeks returned these
parameters to control level without hypoglycemic effect,
indicating the protective role of taurine on endothelium.
Interestingly, same group previously reported that taurine
supplementation (1.5 g per day) for 2 weeks also attenu-
ated the impairment of ﬂow-mediated dilatation in young
cigarette smokers (Fennessy et al. 2003). Furthermore,
while the culture medium conditioned with monocytes
taken from smokers impaired the release of nitric oxide and
increased in endothelin-1 in HUVECs, the levels of nitric
oxide and endothelin-1 returned to control levels in HU-
VECs cultured with the monocyte-conditioned medium
taken from smokers who had been treated with taurine.
Therefore, the suppression of monocyte-endothelium
interaction is likely to be a key action of protective role of
taurine on endothelial function. Since the involvement of
monocyte–endothelium interaction in endothelial dys-
function of diabetic animal models is also demonstrated as
described above, it is possible that same pathway underlies
the action of taurine against endothelial dysfunction in
diabetic patients.
Discussion
As described in this article, numerous studies revealed that
taurine supplementation is beneﬁcial to diabetes and its
complications in several animal models. Moreover, multi-
ple actions of taurine coordinate to protect from diabetes
and complications (Table 2). Especially, suppressive effect
of taurine against oxidative stress is associated with various
pathways in diabetic condition. First, reactivity of taurine
against aldehyde can contribute to the reduction of AGE
and modiﬁed LDL. Second, scavenging action against
HClO can reduce the LDL modiﬁcation and increase in
bioavailability of the NO. Finally, taurine is likely to
inhibit the ROS production via regulation of mitochondria
(reviewed in Schaffer et al. 2009). While very high taurine
concentration is found in mitochondria, several roles of
taurine in mitochondria have been proposed. Taurine-
containing modiﬁed uridine has recently been discovered at
wobble position in mitochondrial transfer RNA (tRNA)
(Suzuki et al. 2002). Taurine-modiﬁed tRNA may play a
crucial role in the translation of proteins responsible for
electron transport (Kirino et al. 2004), suggesting that
taurine depletion might cause a decrease in taurine-modi-
ﬁed tRNA and impairs electron transport capacity. More-
over, buffering property of taurine in mitochondrial matrix
has been reported (Hansen et al. 2010). Therefore, taurine
depletion in diabetes may contribute to mitochondrial
dysfunction and it is possible that restoration of taurine
contributes to normalize mitochondrial function, which
may associate with inhibition of the ROS production from
mitochondria. To elucidate the role of taurine depletion in
mitochondrial function and in the development of diabetic
complications, further studies, such as investigations using
taurine transporter knock-out animals (Ito et al. 2008), will
be required.
Nevertheless, most of clinical studies failed to prove the
beneﬁcial role of taurine on insulin resistance and diabetic
Table 2 Molecular
mechanisms involved in the
beneﬁcial effect of taurine
against diabetic complications
Diabetic complications Effects of taurine
Endothelial dysfunction • Prevention of AGE production
• Scavenging aldehydes ? oxidized LDL;
• Scavenging HClO ? oxidized LDL;,N O :
• LDL cholesterol;
• Inhibition of apoptosis in endothelial cells
• Prevention of VCAM-1, ICAM-1 :?leukocyte-endothelium interaction;
Diabetic nephropathy • TGF-b;?prevention of ﬁbrosis
• Suppression of MAPK cascade, STAT3 ? cell growth
• Cytochrome P450 2E1;?oxidative stress;
Diabetic retinopathy • Oxidative stress;?prevention of Na?/K?/ATPase activity;
• Suppression of VEGF:?retinal vascular function
Diabetic cataract • Oxidative stress ;
• Prevention of protein carbonylation
Diabetic neuropathy • Oxidative stress ; in nerves
• Prevention of the impaired calcium handling in sensory neuron
• Suppression of NGF;
Diabetic cardiomyopathy • Suppression of Bcl-2;?apoptosis;
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123complications, whereas the others revealed the effective-
ness. The discrepancies between animal experiments and
clinical trials might be due to some limitations of clinical
studies, such as a severity of the disease, other medications,
given dose, duration of trial etc. Especially, the given dose
of taurine per body weight is more than 10 times higher in
animal experiments (e.g. diet containing 5% taurine) than
in clinical trials (1.5–3 g taurine per day). Intake of taurine
is thought to be quite safe as well as the amino acids found
in food. While several reports strongly support that taurine
is safe at levels up to 3 g/day, several clinical trials tested
higher taurine dosages without adverse effects (Azuma
et al. 1983, 1985; Shao and Hathcock 2008). Furthermore,
since the pharmacological effect of taurine seems mild but
not powerful, simultaneous therapy by using some medi-
cines is also a problem. At present none of clinical studies
have a sufﬁcient numbers of patients. Therefore, long-term
surveillance with large numbers of patients may be nec-
essary to elucidate the effectiveness of taurine against
diabetes or its complications in clinical study. Moreover,
life style, such as diet, and genetic factors, such as genomic
polymorphisms which relate to individual differences, can
affect to the result of trials. It is known that urinary taurine
concentration in human varies widely among individuals
(Yamori et al. 2001). Brons et al. (2004) reported a wide
variation in the increasing rate of plasma taurine concen-
tration after taurine administration among individuals.
These variations of taurine movement among individuals
must differ dependent not only on life style but also
genomic polymorphisms in taurine-related genes associ-
ated with the kinetics of taurine, such as taurine transporter.
Therefore, we believe that the discovery of the genetic
factors which determine the variation of taurine movement
will help to elucidate the effectiveness of taurine against
diabetes and its complications in humans.
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